ArticleClinical and experimental immunology2002
Detection of antivimentin antibody in sera of patients with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia.
Article in Clinical and experimental immunology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 60 citations in OpenAlex.
- Natural and disease-specific autoantibodies in chronic obstructive pulmonary disease.Clinical and experimental immunology · 2015Trial
- Autoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary Fibrosis.PloS one · 2015Trial
- Immunological mechanisms and therapeutic approaches in pulmonary fibrosis.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Endothelial-to-mesenchymal transition: a precursor to pulmonary arterial remodelling in patients with idiopathic pulmonary fibrosis.ERJ open research · 2023Article
- Immune cells in lens injury repair and fibrosis.Experimental eye research · 2021Review
- Set Up for Failure: Pre-Existing Autoantibodies in Lung Transplant.Frontiers in immunology · 2021Review
- Intrapulmonary Autoantibodies to HSP72 Are Associated with Improved Outcomes in IPF.Journal of immunology research · 2019Article
- The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis.Frontiers in medicine · 2018Review
- Autoimmunity to Vimentin Is Associated with Outcomes of Patients with Idiopathic Pulmonary Fibrosis.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- Idiopathic pulmonary fibrosis and a role for autoimmunity.Immunology and cell biology · 2017Review
- Deficiency of α7 nicotinic acetylcholine receptor attenuates bleomycin-induced lung fibrosis in mice.Molecular medicine (Cambridge, Mass.) · 2017Article
- Immunomodulation by mesenchymal stem cells in treating human autoimmune disease-associated lung fibrosis.Stem cell research & therapy · 2016Article
- Article
- C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis.American journal of respiratory and critical care medicine · 2014Article
- BPIFB1 is a lung-specific autoantigen associated with interstitial lung disease.Science translational medicine · 2013Article
- Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Incidence and mortality of obstructive lung disease in rheumatoid arthritis: a population-based study.Arthritis care & research · 2013Article
- Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses.American journal of respiratory and critical care medicine · 2013Article
- Molecular and cellular mechanisms of pulmonary fibrosis.Fibrogenesis & tissue repair · 2012Article
- Alteration of fibroblast phenotype by asbestos-induced autoantibodies.Journal of immunotoxicology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has been suggested that the humoral immune system plays a role in the pathogenesis of non-specific interstitial pneumonia (NSIP). Although some circulating autoantibodies to cytoskeletal protein(s) have been suggested, the antimyofibroblast antibody has not been investigated in patients with idiopathic pulmonary fibrosis (IPF) and NSIP. The purpose of this study is to evaluate the existence of antimyofibroblast antibody in the sera of patients with IPF and NSIP. The MRC5 cell line was used as a model of myofibroblast. The anti-MRC5 cell antibody was characterized in a patient with NSIP using Western blotting. Since we found that one of the anti-MRC5 antibodies was an antivimentin antibody, we established an enzyme-linked immunosorbent assay (ELISA) to measure the levels of antivimentin antibody in the sera of patients with IPF (n = 12) and NSIP (n = 23). Initially, two anti-MRC5 cell antibodies were detected in the sera of patients with NSIP, one of which was characterized as the antivimentin antibody by Western blotting. The other was characterized as an antivimentin fragment antibody. We established an ELISA to measure the antivimentin antibody and found significantly higher levels in patients with IPF and NSIP than in normal volunteers. One of the anti-MRC5 cell antibodies in the serum of a patient with NSIP was against vimentin. The serum levels of antivimentin antibody were increased in patients with IPF and NSIP compared with that of normal volunteers. These results suggest that the antivimentin antibody may be involved in the process of lung injury in IPF and NSIP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.